Literature DB >> 27324503

Medical hospitalizations in prostate cancer survivors.

Jerome Gnanaraj1, Shobana Balakrishnan2, Zarish Umar3, Emmanuel S Antonarakis4, Christian P Pavlovich5, Scott M Wright6, Waseem Khaliq6.   

Abstract

The objectives of the study were to explore the context and reasons for medical hospitalizations among prostate cancer survivors and to study their relationship with obesity and the type of prostate cancer treatment. A retrospective review of medical records was performed at an academic institution for male patients aged 40 years and older who were diagnosed and/or treated for prostate cancer 2 years prior to the study's observation period from January 2008 to December 2010. Unpaired t test, ANOVA, and Chi-square tests were used to compare patients' characteristics, admission types, and medical comorbidities by body mass index (BMI) and prostate cancer treatment. Mean age for the study population was 76 years (SD = 9.2). Two hundred and forty-five prostate cancer survivors were stratified into two groups: non-obese (BMI < 30 kg/m(2)) and obese (BMI ≥ 30 kg/m(2)). The study population's characteristics analyzed by BMI were similar including Gleason score, presence of metastatic disease and genitourinary-related side effects. Only 13 % of admissions were for complaints related to their genitourinary system. Neither the specific treatment that the patients had received for their prostate cancer, nor obesity was associated with the reasons for their medical admission. Survivorship after having a diagnosis of prostate cancer is often lengthy, and these men are at risk of being hospitalized, as they get older. From this inquiry, it has become clear that neither body mass index nor prior therapy is associated with specific admission characteristics, and only a minority of such admissions was directly related to prostate cancer or the genitourinary tract.

Entities:  

Keywords:  Medical hospitalizations; Obesity; Prostate cancer survivors; Prostate cancer treatments

Mesh:

Year:  2016        PMID: 27324503     DOI: 10.1007/s12032-016-0796-y

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  17 in total

1.  Quality-of-life impact of primary treatments for localized prostate cancer in patients without hormonal treatment.

Authors:  Yolanda Pardo; Ferran Guedea; Ferrán Aguiló; Pablo Fernández; Víctor Macías; Alfonso Mariño; Asunción Hervás; Ismael Herruzo; María José Ortiz; Javier Ponce de León; Jordi Craven-Bratle; José Francisco Suárez; Ana Boladeras; Àngels Pont; Adriana Ayala; Gemma Sancho; Evelyn Martínez; Jordi Alonso; Montserrat Ferrer
Journal:  J Clin Oncol       Date:  2010-10-04       Impact factor: 44.544

2.  Guideline for the management of clinically localized prostate cancer: 2007 update.

Authors:  Ian Thompson; James Brantley Thrasher; Gunnar Aus; Arthur L Burnett; Edith D Canby-Hagino; Michael S Cookson; Anthony V D'Amico; Roger R Dmochowski; David T Eton; Jeffrey D Forman; S Larry Goldenberg; Javier Hernandez; Celestia S Higano; Stephen R Kraus; Judd W Moul; Catherine M Tangen
Journal:  J Urol       Date:  2007-06       Impact factor: 7.450

3.  Cause of death in older men after the diagnosis of prostate cancer.

Authors:  William B Grant
Journal:  J Am Geriatr Soc       Date:  2009-05       Impact factor: 5.562

4.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

Review 5.  Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis.

Authors:  Yin Cao; Jing Ma
Journal:  Cancer Prev Res (Phila)       Date:  2011-01-13

6.  Health-related quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer.

Authors:  J B Madalinska; M L Essink-Bot; H J de Koning; W J Kirkels; P J van der Maas; F H Schröder
Journal:  J Clin Oncol       Date:  2001-03-15       Impact factor: 44.544

7.  Management of severe urethral complications of prostate cancer therapy.

Authors:  Sean P Elliott; Jack W McAninch; Thomas Chi; Sean M Doyle; Viraj A Master
Journal:  J Urol       Date:  2006-12       Impact factor: 7.450

8.  Long-term follow-up of conservatively managed incidental carcinoma of the prostate: a multivariate analysis of prognostic factors.

Authors:  David Robinson; Gunnar Aus; Julia Bak; Tomasz Gorecki; Anders Herder; Johan Rosell; Eberhard Varenhorst
Journal:  Scand J Urol Nephrol       Date:  2007

Review 9.  Obesity and prostate cancer: weighing the evidence.

Authors:  Emma H Allott; Elizabeth M Masko; Stephen J Freedland
Journal:  Eur Urol       Date:  2012-11-15       Impact factor: 20.096

10.  Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomes.

Authors:  Prasanna Sooriakumaran; Tommy Nyberg; Olof Akre; Leif Haendler; Inge Heus; Mats Olsson; Stefan Carlsson; Monique J Roobol; Gunnar Steineck; Peter Wiklund
Journal:  BMJ       Date:  2014-02-26
View more
  2 in total

1.  Predictors of recurrent hospital admissions among prostate cancer survivors.

Authors:  Jerome Gnanaraj; Zarish Umar; Shobana Balakrishnan; Lucia Ponor; Edward James Wright; Waseem Khaliq
Journal:  Med Oncol       Date:  2017-07-27       Impact factor: 3.064

2.  Profile of hospitalizations for neoplasms in the Brazilian Unified Health System: a time-series study.

Authors:  Analy da Silva Machado; Anaely da Silva Machado; Dirce Bellezi Guilhem
Journal:  Rev Saude Publica       Date:  2021-11-22       Impact factor: 2.106

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.